Patents by Inventor Charles E. Zeilig

Charles E. Zeilig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170246241
    Abstract: Tumor cells exhibit consistent abnormalities in calcium regulation. The present disclosure teaches methods by which such differences are exploited to induce Apoptosis selectively in tumor/cancer cells while sparing normal cells. These methods are based upon employing drugs that, acting in synergistic combinations, trigger selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 31, 2017
    Inventor: Charles E. Zeilig
  • Publication number: 20140065246
    Abstract: Tumor cells exhibit consistent abnormalities in calcium regulation. The present disclosure teaches methods by which such differences are exploited to induce Apoptosis selectively in tumor/cancer cells while sparing normal cells. These methods are based upon employing drugs that, acting in synergistic combinations, trigger selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 6, 2014
    Inventor: Charles E. Zeilig
  • Publication number: 20110098232
    Abstract: Available evidence indicates that tumor cells exhibit consistent abnormalities in Calcium influx and intracellular storage of sequestered Calcium when compared to normal cells. The present invention provides clinical methods by which such differences are exploited to induce Apoptosis selectively in tumor cells while sparing normal cells. These methods are based upon employing drugs that, acting alone or in synergistic combinations, produce an increase in intracellular Calcium loading such that either or both of two major Apoptotic pathways are triggered to produce selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that Calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.
    Type: Application
    Filed: October 25, 2010
    Publication date: April 28, 2011
    Inventor: Charles E. Zeilig